TitleMethods for Selecting and Identifying Cancer Stem Cells
OwnerUniversity of California
Cancer stem cells (CSC) have been identified in several types of cancer, including leukemia. While CSC are key to the progression of cancer and can be resistant to chemotherapeutic drugs, Leukemia stem cells (LSC) are also resistant to most treatments, such as radiotherapy and chemotherapy. LSC are also considered the main cause of drug resistance and disease relapse. There has long been a need for methods of identifying and isolating LSC from an individual or cell culture. LSCs have been successfully identified and characterized in certain types of leukemia, such as AML; however, whether LSC exist in acute lymphoblastic leukemia (ALL), the most common childhood leukemia, is unknown as no distinct phenotypic LSC marker has been identified.Researchers at the University of California, Davis have developed methods for identifying LSC in B-cell type ALL using fluorescent tagged metabolites. These methods can also be used to identify a subpopulation of LSC within a sample. Additionally, these methods have potential applications in the development of LSC-targeted therapeutics and can be used in drug screening methods or experimental analysis to determine or predict disease progression, relapse, and/or the development of disease resistance. LSC stem cells can also be characterized based on the expression of LSC markers and therefore can be used to identify populations of LSC.Applications Leukemia stem cell therapeuticsCancer stem cell therapeuticsCancer progression predictionsDetermining relapseDetermining disease resistanceFeatures/Benefits Identifying and isolating subpopulations of leukemia stem cells in acute lymphoblastic leukemia 
Owner: 
University of California
Dislike
0
Description

Cancer stem cells (CSC) have been identified in several types of cancer, including leukemia. While CSC are key to the progression of cancer and can be resistant to chemotherapeutic drugs, Leukemia stem cells (LSC) are also resistant to most treatments, such as radiotherapy and chemotherapy. LSC are also considered the main cause of drug resistance and disease relapse. There has long been a need for methods of identifying and isolating LSC from an individual or cell culture. LSCs have been successfully identified and characterized in certain types of leukemia, such as AML; however, whether LSC exist in acute lymphoblastic leukemia (ALL), the most common childhood leukemia, is unknown as no distinct phenotypic LSC marker has been identified.

Researchers at the University of California, Davis have developed methods for identifying LSC in B-cell type ALL using fluorescent tagged metabolites. These methods can also be used to identify a subpopulation of LSC within a sample. Additionally, these methods have potential applications in the development of LSC-targeted therapeutics and can be used in drug screening methods or experimental analysis to determine or predict disease progression, relapse, and/or the development of disease resistance. LSC stem cells can also be characterized based on the expression of LSC markers and therefore can be used to identify populations of LSC.

Applications

 

  • Leukemia stem cell therapeutics
  • Cancer stem cell therapeutics
  • Cancer progression predictions
  • Determining relapse
  • Determining disease resistance

Features/Benefits

 

  • Identifying and isolating subpopulations of leukemia stem cells in acute lymphoblastic leukemia

 

Date:01-08-2017
Applicants:University of California
Access to additional documentation:Please inquire
Case Ref:UC Case 2013-057-0
Application number:US20180011100
Support from inventors:Please inquire
Industry:Healthcare
Meta information:
Meta title:
Please fill out the form and press 'send'
Contact Seller
Please provide your contact information below.

Use this form to contact the IP-owner - you should provide an email of your choice for contact. Indicate your interest/reason for the contact.
Disclaimer: Licentix do not guarantee that message sent using this form will be read by the recipient. Please contact us if you are not recieving any response.